- Email: [email protected]
Re: Retrograde Transport of Radiolabelled Botulinum Neurotoxin Type A to the CNS after Intradetrusor Injection in Rats
482
VOIDING FUNCTION, BLADDER PHYSIOLOGY AND PHARMACOLOGY, AND FEMALE UROLOGY
Re: Trends in Mesh Use for Pelvic Organ Prolapse Repair from the Medicare Database L. C. Wang, B. Al Hussein Al Awamlh, J. C. Hu, M. A. Laudano, W. L. Davison, M. L. Schulster, F. Zhao, B. Chughtai and R. K. Lee Department of Urology, Weill Medical College of Cornell University, New York, New York, and Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China Urology 2015; 86: 885e891. doi: 10.1016/j.urology.2015.08.022
Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/26344153 Editorial Comment: This article looked at a slightly different population than the preceding article by Younger et al. These authors used 5% sample files from the Medicare claims database from 2001 to 2011. Nonmesh surgery as a percent of total pelvic organ prolapse surgery for the years 2007 to 2011 compared with the figures of Younger et al are as follows: 89.5% vs 62% for 2007; 65.1% vs 66% for 2008; 63.3% vs 69% for 2009; 61.5% vs 74% for 2010, and 64.8% vs 76% for 2011. As a comparison, the nonmesh data in this article included a 98% and 96.1% figure for no mesh utilized in 2005 and 2006, respectively. The authors wisely conclude, “The use of transvaginal mesh reflects the classic attempt to leverage new technologies to enhance surgical repair. However, its use serves as a warning that all new technologies must eventually pass the scrutiny of not only rigorous preclinical testing, but more importantly clinical experience.” Alan J. Wein, MD, PhD (hon)
Re: Retrograde Transport of Radiolabelled Botulinum Neurotoxin Type A to the CNS after Intradetrusor Injection in Rats D. Papagiannopoulou, L. Vardouli, F. Dimitriadis and A. Apostolidis Department of Medicinal Chemistry, School of Pharmacy, and Department of Pharmacology and 2nd Department of Urology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece BJU Int 2016; 117: 697e704. doi: 10.1111/bju.13163
Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/25912438 Editorial Comment: It is interesting that the antimuscarinics, the beta agonists approved for clinical use and botulinum toxin type A (BoNT/A) were originally thought to exert their effect on the lower urinary tract by directly affecting bladder smooth muscle contractility or the release of the excitatory neurotransmitter. Attention has shifted, in some cases more than others, to a primarily afferent mode of action, and now perhaps a central nervous system action based on retrograde transport, at least for BoNT/A, providing, as the authors state, “the background for a possible direct effect of BoNT/A in central nervous system structures involved in the control of bladder function.” Alan J. Wein, MD, PhD (hon)
Re: Comparison of the Effects of b3-Adrenoceptor Agonism on Urinary Bladder Function on Conscious, Anesthetized, and Spinal Cord Injured Rats J. B. Beauval, V. Guilloteau, M. Cappellini, T. D. Westfall, P. Rischmann, S. Palea, and P. Lluel X. Game UROsphere, Faculty of Pharmaceutical Sciences and Department of Urology, Andrology and Renal Transplantation, and INSERM I2MC, Rangueil University Hospital, Toulouse, France Neurourol Urodyn 2015; 34: 578e585. doi: 10.1002/nau.22629
Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/24938622 Editorial Comment: This rodent study suggests that b3-adrenergic agonists would be effective in treating neurogenic detrusor overactivity. If nonvoiding contractions in spinal cord injury subjects are generated by increase in afferent activity, b3-adrenergic agonists could decrease the frequency
VOIDING FUNCTION, BLADDER PHYSIOLOGY AND PHARMACOLOGY, AND FEMALE UROLOGY
Re: Trends in Mesh Use for Pelvic Organ Prolapse Repair from the Medicare Database L. C. Wang, B. Al Hussein Al Awamlh, J. C. Hu, M. A. Laudano, W. L. Davison, M. L. Schulster, F. Zhao, B. Chughtai and R. K. Lee Department of Urology, Weill Medical College of Cornell University, New York, New York, and Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China Urology 2015; 86: 885e891. doi: 10.1016/j.urology.2015.08.022
Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/26344153 Editorial Comment: This article looked at a slightly different population than the preceding article by Younger et al. These authors used 5% sample files from the Medicare claims database from 2001 to 2011. Nonmesh surgery as a percent of total pelvic organ prolapse surgery for the years 2007 to 2011 compared with the figures of Younger et al are as follows: 89.5% vs 62% for 2007; 65.1% vs 66% for 2008; 63.3% vs 69% for 2009; 61.5% vs 74% for 2010, and 64.8% vs 76% for 2011. As a comparison, the nonmesh data in this article included a 98% and 96.1% figure for no mesh utilized in 2005 and 2006, respectively. The authors wisely conclude, “The use of transvaginal mesh reflects the classic attempt to leverage new technologies to enhance surgical repair. However, its use serves as a warning that all new technologies must eventually pass the scrutiny of not only rigorous preclinical testing, but more importantly clinical experience.” Alan J. Wein, MD, PhD (hon)
Re: Retrograde Transport of Radiolabelled Botulinum Neurotoxin Type A to the CNS after Intradetrusor Injection in Rats D. Papagiannopoulou, L. Vardouli, F. Dimitriadis and A. Apostolidis Department of Medicinal Chemistry, School of Pharmacy, and Department of Pharmacology and 2nd Department of Urology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece BJU Int 2016; 117: 697e704. doi: 10.1111/bju.13163
Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/25912438 Editorial Comment: It is interesting that the antimuscarinics, the beta agonists approved for clinical use and botulinum toxin type A (BoNT/A) were originally thought to exert their effect on the lower urinary tract by directly affecting bladder smooth muscle contractility or the release of the excitatory neurotransmitter. Attention has shifted, in some cases more than others, to a primarily afferent mode of action, and now perhaps a central nervous system action based on retrograde transport, at least for BoNT/A, providing, as the authors state, “the background for a possible direct effect of BoNT/A in central nervous system structures involved in the control of bladder function.” Alan J. Wein, MD, PhD (hon)
Re: Comparison of the Effects of b3-Adrenoceptor Agonism on Urinary Bladder Function on Conscious, Anesthetized, and Spinal Cord Injured Rats J. B. Beauval, V. Guilloteau, M. Cappellini, T. D. Westfall, P. Rischmann, S. Palea, and P. Lluel X. Game UROsphere, Faculty of Pharmaceutical Sciences and Department of Urology, Andrology and Renal Transplantation, and INSERM I2MC, Rangueil University Hospital, Toulouse, France Neurourol Urodyn 2015; 34: 578e585. doi: 10.1002/nau.22629
Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/24938622 Editorial Comment: This rodent study suggests that b3-adrenergic agonists would be effective in treating neurogenic detrusor overactivity. If nonvoiding contractions in spinal cord injury subjects are generated by increase in afferent activity, b3-adrenergic agonists could decrease the frequency